VivoSeq
Other

Primary Sjögren's Syndrome

1

Pipeline Programs↗

5

Active Trials↗

11

Companies Involved↗

Primary Sjögren's Syndrome is an early-stage landscape with 1 program across 11 companies. The most active players are Eli Lilly, Novartis, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Novartis logo

Novartis

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalArgenx logo

Argenx

0 programs

PreclinicalInstitut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

0 programs

PreclinicalS

Samjin Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

IMVT-1402

Immunovant Sciences GmbH

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

34

clinical trials

Completed22 · 65%
Terminated5 · 15%
Recruiting4 · 12%
Unknown status1 · 3%
Not yet recruiting1 · 3%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

34 trials

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
Recruiting·Argenx logoArgenx·Phase 3·NCT06684847·580 enrolled
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04981145·78 enrolled
New Clinical End-points in Patients With Primary Sjögren's Syndrome
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05113004·300 enrolled
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06979531·180 enrolled
Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome
Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT06862284·30 enrolled
Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome
Completed·UUniversity Medical Center Groningen·Phase 3·NCT02067910·80 enrolled
PD of VAY736 in Patients With Primary Sjögren's Syndrome
Completed·Novartis logoNovartis·Phase 2·NCT02149420·27 enrolled
Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome
Completed·SSeoul National University Hospital·Phase 3·NCT01601028·39 enrolled
N-acetylcysteine for Primary Sjögren's Syndrome
Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT04793646·60 enrolled
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
Completed·Novartis logoNovartis·Phase 2·NCT02775916·30 enrolled
Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients
Completed·Institut de Recherches Internationales Servier logoInstitut de Recherches Internationales Servier·Phase 2·NCT04605978·48 enrolled
Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01160666·20 enrolled
Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome
Completed·SSamjin Pharmaceutical Co., Ltd.·Phase 2·NCT05269810·28 enrolled
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Completed·Argenx logoArgenx·Phase 2·NCT06203457·24 enrolled
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
Completed·RRemeGen Co., Ltd.·Phase 2·NCT04078386·42 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)